First results of SURE-02: A phase 2 study of neoadjuvant sacituzumab govitecan (SG) plus pembrolizumab (Pembro), followed by response-adapted bladder sparing and adjuvant pembro, in patients with muscle-invasive bladder cancer (MIBC). | Abstract #4518 | Saturday, May 31 | 12:30 – 1:30 PM PT | Andrea Necchi, M.D. | Arie Crown Theater | Live Stream | |
Prognostic validation of six androgen production, uptake, and conversion genes (APUC-6) in the CHAARTED prostate cancer trial. | Abstract #5089 | Poster Bd #288 | Monday, June 2 | 9:00 AM – 12:00 PM CT | Xiaolei Shi, M.D., Ph.D. | Hall A – Posters and Exhibits | On Demand | |
First survival outcomes and biomarker results of SURE-01: Neoadjuvant sacituzumab govitecan (SG) monotherapy, followed by radical cystectomy (RC), in patients with muscle-invasive urothelial bladder cancer (MIBC). | Abstract #4591 | Poster Bd #391 | Monday, June 2 | 9:00 AM – 12:00 PM CT | Brigida Anna Maiorano, MD | Hall A – Posters and Exhibits | On Demand | |
Overall survival and biomarker results of NURE-Combo: A phase 2 study of neoadjuvant nivolumab (NIVO) and nab-paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (pts) with muscle-invasive bladder cancer (MIBC). | Abstract #4594| Poster Bd #394: | Monday, June 2 | 9:00 AM – 12:00 PM CT | Chiara Mercinelli, M.D. | Hall A – Posters and Exhibits | On Demand | |
Five-year median follow-up update of PURE-01: A phase 2 study of neoadjuvant pembrolizumab followed by radical cystectomy in patients with muscle-invasive bladder cancer (MIBC). | Abstract #4595 | Poster Bd #395 | Monday, June 2 | 9:00 AM – 12:00 PM CT | Valentina Tateo, M.D. | Hall A – Posters and Exhibits | On Demand | |
Transcriptome classification of PTEN inactivation to predict survival benefit from docetaxel at start of androgen deprivation therapy (ADT) for metastatic prostate cancer (PC): An ancillary study of the STAMPEDE trials. | Abstract #5003 | Monday, June 2 | 9:45 AM – 12:45 PM CT | Emily Grist, Ph.D., MBBS, MRCP, BSc | Hall D1 | Live Stream | |